Global Xerostomia (Dry Mouth) Market Valued at $1.1 billion in 2025, Set to Grow at a 7.1% CAGR

Xerostomia (dry mouth) market was valued at $1.1 billion in 2025 and is projected to reach $2.2 billion by 2035, growing at a CAGR of 7.1% during the forecast Period (2026-2035). Advancements in regenerative therapies are supporting the growth of the global xerostomia market by addressing unmet needs in salivary gland dysfunction. Regulatory progress, including FDA Fast Track designations, is accelerating the development of targeted treatments. For instance, in February 2026, Cell therapy for Sjögren’s disease, aimed at treating xerostomia (dry mouth), received FDA Fast Track designation. Developed by the UW Program for Advanced Cell Therapy, it is currently being tested in a Phase 0 clinical trial. This expedited review process, meant for serious conditions with unmet needs, can shorten the lengthy FDA approval timeline. Xerostomia significantly impacts daily functions and health. The innovative therapy utilizes interferon-?-primed autologous mesenchymal stromal cells to stimulate the immune system and restore tissue.

Browse the full report description of “Xerostomia (Dry Mouth) Market Size, Share & Trends Analysis by Product (Artificial Saliva / Saliva Substitutes, Salivary Stimulants / Sialogogues, Biologic / Regenerative Therapies), By Drug Type (Over the Counter (OTC), and Prescription), By Formulation (Sprays, Mouthwashes / Rinses, Gels, Lozenges / Tablets, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies / E commerce), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/xerostomia-market

FDA Clears Gene Therapy for Radiation-Induced Dry Mouth

• In November 2024, the FDA has cleared an IND application for RXRG001, a circular RNA?based therapy being studied for radiation?induced xerostomia (dry mouth caused by radiation damage to salivary glands). This enables a Phase?1/2a clinical trial. Although not yet approved for widespread use, this is a noteworthy development in gene?based approaches to treating salivary dysfunction.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product
  • By Drug Type
  • BY Formulation
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Church & Dwight Co., Inc., Colgate-Palmolive Co., GlaxoSmithKline plc (GSK), Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Xerostomia (Dry Mouth) Market Report Segment

By Product

• Artificial Saliva / Saliva Substitutes
• Salivary Stimulants / Sialogogues
• Biologic / Regenerative Therapies

By Drug Type

• Over?the?Counter (OTC)
• Prescription

By Formulation

• Sprays
• Mouthwashes / Rinses
• Gels
• Lozenges / Tablets
• Others (Mouthwashes / Oral Rinses, and Oral Liquids)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies / E?commerce

Global Xerostomia (Dry Mouth) Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/xerostomia-market